Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients

A M Romanic1, C L Burns-Kurtis, Z Ao

  • 1Department of Cardiovascular Pharmacology, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA. anne_romanic-1@sbphrd.com

Insights

Matrix metalloproteinases (MT-MMPs) are upregulated in diabetic kidneys, contributing to tubular atrophy. This suggests MT5-MMP plays a role in diabetic nephropathy and kidney failure.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Nephrology

Background:

  • Matrix metalloproteinases (MMPs) degrade extracellular matrix (ECM).
  • Membrane-type MMPs (MT-MMPs) are cell-surface anchored MMPs involved in ECM remodeling.
  • MT5-MMP activates pro-MMP-2, a key enzyme in ECM degradation.

Purpose of the Study:

  • To investigate the expression of MT5-MMP in human kidney tissue.
  • To determine the role of MT5-MMP in diabetic nephropathy and renal tubular atrophy.

Main Methods:

  • mRNA and protein expression analysis of MT5-MMP in human kidney samples.
  • Immunohistochemistry to localize MT5-MMP expression.
  • Analysis of MMP-2 activation in diabetic kidney samples.

Main Results:

  • MT5-MMP is expressed in human kidney tubules and upregulated in diabetes.
  • Active MMP-2 is also upregulated in diabetic kidney samples.
  • MT5-MMP expression in tubular epithelial cells correlates with tubular atrophy.

Conclusions:

  • Elevated MT5-MMP expression in diabetes may activate pro-MMP-2, contributing to tubular remodeling.
  • MT5-MMP is implicated in the pathogenesis of diabetic nephropathy and renal failure.
  • This study provides the first evidence linking MT-MMPs to diabetic kidney disease.